The baby in the news for being cured of AIDS was given two drugs sold by ViiV Healthcare and Abbott Laboratories.

ViiV Healthcare is a joint venture formed by GlaxoSmithKline and Pfizer in 2009 to focus only on HIV medicines. ViiV Healthcare's U.S. headquarters is in Research Triangle Park.

Trimeris shareholders will meet Nov. 2 to vote on the proposed sale of the AIDS-drug company to a Massachusetts drug-development company.

Trimeris, which is based in Durham and is publicly traded, has agreed to be acquired by privately held Synageva in an all-stock deal.

The deal calls for the investors in Synageva to own 75 percent of the combined company's outstanding shares, with Trimeris shareholders owning the remaining 25 percent.

The combined business will be called Synageva and will be run by the current Synageva CEO, Sanj K. Patel. After the merger, the company will have no presence in Durham.

Trimeris has been seeking a buyer for years.

It once employed 150 workers but now has fewer than a handful and has no products under development. Its sole business is collecting royalty checks for sales of the AIDS drug Fuzeon from its marketing partner Roche.

Those checks have been getting smaller over the past two years as sales are on the decline.

Trimeris today reported mixed sales results for its AIDS drug Fuzeon.

Sales of the powerful AIDS medication totaled $29.8 million in the third quarter, down 35 percent from a year ago, the Durham company reported this afternoon after the markets closed. However, sales were two percent higher than the second quarter.

Trimeris, which has agreed to be acquired by a Korean company, receives royalty payments from the sale of Fuzeon, which is manufactured and sold by its marketing partner, the Swiss pharmaceutical giant Roche.